Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Letrozole extends time to tumor progression in mouse model
April 6th, 2004
In a mouse model of human breast cancer, the drug letrozole more effectively extends time to tumor progression than tamoxifen or various combinations and dosing schedules of tamoxifen plus letrozole. Clinical data from patients with estrogen receptor-positive breast cancer suggest that aromatase inhibitors, such as letrozole, manufactured by Novartis Pharmaceuticals, are more effective and better tolerated than the anti-estrogen tamoxifen. To investigate ways to optimize treatment using letrozole and tamoxifen, Brian J. Long and Angela M. Brodie, PhD, of the University of Maryland School of Medicine, Baltimore, and colleagues treated a mouse xenograft breast cancer...
Source: Cancer Weekly (2004-04-06)
|
